Roche Dec 8, 2022 New HER2-Low Category Spurring Efforts to Understand Breast Cancer Biology, Develop Better Tests Premium Nov 29, 2022 Genentech to Withdraw First-Line Tecentriq Bladder Cancer Indication Nov 23, 2022 Cancer Research UK Opens Precision Medicine Platform Trial for Rare Cancers Nov 18, 2022 NeoGenomics, ImmunoGen Ink Testing Deal for Newly Approved Folate Receptor Drug Nov 15, 2022 FDA Approves ImmunoGen's Elahere for Folate Receptor Alpha-Positive Ovarian Cancer Oct 20, 2022 Roche Licenses Hookipa Pharma's KRAS-Targeted Immunotherapy Oct 18, 2022 Roche Q3 Pharma Revenues Decline 6 Percent Due to Lower Sales of COVID-19 Treatments Premium Oct 4, 2022 FDA Approves Roche Antibody Test as CDx for Enhertu in HER2-Low Breast Cancer Patients Sep 11, 2022 Selective Estrogen Receptor Degraders, Modulators Show Promise in ESR1-Mutant Breast Cancer Premium Sep 9, 2022 Roche Obtains CE Mark for Ventana PD-L1 Assay as CDx for Libtayo Sep 7, 2022 Roche to Acquire Good Therapeutics for $250M Aug 26, 2022 In Brief This Week: Immatics, Aktis Oncology, Daiichi Sankyo, Roche Pharma India, Genetron Aug 24, 2022 Roche Gets Expanded CE Mark for Ventana PD-L1 Assay to ID NSCLC Patients for Tecentriq Aug 11, 2022 Roche Nabs FDA Label Expansion for Ventana CDx Panel Jul 21, 2022 Roche Sees More Growth Opportunities for Phesgo, Tecentriq; Still Optimistic on Tiragolumab Premium Jul 14, 2022 Synthetic Control Arms Finding Stronger Footing in Precision Oncology Trials, Regulatory Submissions Premium Jul 1, 2022 Treos Bio, Roche Begin Combination Immunotherapy Study in Microsatellite-Stable Colorectal Cancer Jun 10, 2022 Norway's Fledgling Precision Oncology Effort Finding Early Success Premium Jun 10, 2022 In Brief This Week: Kazia Therapeutics, ImaginAb, Roche, ASCO, HealthVerity, Massive Bio, AdhereTech Jun 9, 2022 FDA Approves Foundation Medicine Test as CDx With Roche's Rozlytrek Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer